Emmanuel Aisabokhae

Back to our people page Back to Locations Back to Back to Article

Principal

Emmanuel has 15+ years experience in clinical practice, biopharma operations and healthcare consulting, across Europe, Middle East & N. America

Areas of Focus

Healthcare & Life Sciences

Strategy

Education

Manchester Business School

MBA

Manchester University

Master of Pharmacy

Past Experience

Arthur D. Little

Healthcare & Life Sciences / Manager

Allagium Therapeutics

Drug development

Johnson & Johnson

R&D/Sales/Marketing/Business Dev

National Health Service, UK

Pharmacist

Emmanuel is a Principal based in our New York office. He is a core member of the Healthcare & Lifesciences practice and advises clients on a range of topics including clinical trial acceleration, drug launch preparation and post patent expiry value maximization.

Emmanuel is also a topic expert in pharmacy operations both in the public and private sectors.

Prior to working at Arthur D. Little, Emmanuel worked as a Pharmacist in the UK National Health Service where he gained experience in both public and private sector pharmacy operations, as well as clinical experience across several therapy areas including general medicine, psychiatry, pediatrics, oncology and ophthalmology.

Emmanuel also has multi-function and multi-therapy area experience from Johnson & Johnson Pharmaceuticals and Allagium Therapeutics.

Emmanuel holds a MBA from Manchester Business School and Master of Pharmacy degree from Manchester University

Healthcare & Life Sciences

Accelerating cures

Patient recruitment drives success in clinical trial execution — but is increasingly difficult. To overcome this challenge and achieve wins, clinical trial sponsors must inspire study teams to beat clinical trial patient-recruitment timeline targets. This Viewpoint provides insights, case studies, and data outcomes of clinical trials that achieved accelerated patient recruitment and shows how this was accomplished.

Find out more

Healthcare & Life Sciences

Why patient centricity is key to long-term pharma company success

Patient centricity seems to be an obvious focus for pharmaceutical companies. After all, their core business is to develop drugs and treatments to meet specific patient needs. Yet, patient centricity is not evident across the end-to-end pharma value chain, from identifying unmet patient needs through drug discovery and development to product availability and treatment. For example, on average, 30% of patients leave clinical trials before their scheduled treatment completion date, often because of the high burden of the trials on their lives.

Find out more

Healthcare & Life Sciences

Elixir of the afterlife

Emmanuel Aisabokhae, Ben Enejo

Find out more

Healthcare & Life Sciences

Pursuing excellence: What’s next for finance in healthcare?

Vikas Kharbanda, Emmanuel Aisabokhae

Find out more

Healthcare & Life Sciences

CAR-T on site: Forgoing the extra mile

Emmanuel Aisabokhae, Ben Enejo

CAR-T (chimeric antigen receptor T-cell) therapy involves the use of genetically re-engineered versions of a patient’s own T-cells to find cancer cells and defeat them. As of March 2020, there are two CAR-T therapies licensed for use – Kymriah® and Yescarta®. CAR-T has pushed the boundaries of medicine, and the success observed in patient treatment has created interest in the use of CAR-T to treat a number of other types of tumors. This is evidenced by the number of clinical trials involving the use of CAR-T to treat a range of cancers (Figures below).

Find out more